The Conversation

Why do essential medicines still fail to reach millions of people in developing countries? As economists Lucy Xiaolu Wang and Nahim Bin Zahur explain, part of the issue is how drugs are bought and sold. In an article commissioned by my colleague Vivian Lam, they dive into the high-stakes world of global drug procurement, looking at the hard choices countries face in getting treatments to patients.

One increasingly popular strategy is what economists call “pooled procurement” – when countries band together to buy medicines in bulk. It often leads to lower prices and more reliable supply. But pooling isn’t a magic fix. The authors show how it can come with trade-offs such as longer lead times and less flexibility, factors that become a problem in emergencies or when political winds shift.

And shift they have: Just consider how recent U.S. foreign aid cuts are already straining health systems that depend on international support. This isn’t just a supply-chain story – it’s about how economics shapes life-and-death decisions worldwide.

Tracy Walsh

Economy + Business Editor
The Conversation U.S.

When developing countries band together, lifesaving drugs become cheaper and easier to buy − with trade-offs

Lucy Xiaolu Wang, UMass Amherst; Nahim Bin Zahur, Queen's University, Ontario

Pharmaceutical companies have little incentive to sell drugs to countries that can’t afford them. But bargaining together can increase access to vital treatments worldwide.

Essential briefings

The Middle East is a major flight hub. How do airlines keep passengers safe during conflict?

Federal R&D funding boosts productivity for the whole economy − making big cuts to such government spending unwise

The battle for TikTok is at the forefront of a deeper geopolitical trend

Not all insecure work has to be a ‘bad job’: research shows job design can make a big difference

Quote of the week 💬

Law

Work

Entrepreneurship

Inequality

Regulation

Chart of the week 📊

More from The Conversation